TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02964000

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level 1 Watt
Description: The Phoenix Thera-Lase System will be on 1 watt

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix Thera-Lase System 42
Description: The Phoenix Thera-Lase System will be on 42 watts

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix Thera-Lase System 74
Description: The Phoenix Thera-Lase System will be on 74 watts
Study: NCT02134925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC1 Peptide-Poly-ICLC Vaccine
Description: Given SC
Study: NCT02635906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 hours
Description: BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 hours
Description: BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
Study: NCT02134925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given SC
Study: NCT01550809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iBolus
Description: Insulin bolus calculated from data obtained through CGM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tBolus (traditional bolus)
Description: Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
Study: NCT00847002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Wound Care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexitouch System with Standard Wound Care
Study: NCT02352844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Study: NCT03313700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Distal Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case, robotic distal gastrectomy will be performed in the experimental group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Distal Gastrectomy
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic distal gastrectomy will be performed in the comparator group.
Study: NCT01377662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OND-PR002 and MPh-IR
Description: Drug: OND-PR002~Single daily oral doses of 8 mg Ond-PR002~Drug: MPh-IR~Single daily oral doses of 20 mg MPh-IR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR
Description: Single daily oral doses
Study: NCT00590863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI + placebo
Description: Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram + Bupropion SR
Description: Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR + Mirtazapine
Description: Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
Study: NCT04603118

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Optic ultrasonography
Study: NCT04254848

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral stereognostic test
Description: Six test pieces were selected from the 20 shapes of test pieces from National Institute of Dental Research. The test pieces comprises of 6 shaped forms which include circle, plus, square, rectangular, triangle and toroid shaped. A 2mm stainless steel wire was bent forming the test piece shape following the standard dimensions (13mm length and 2mm thickness)as described by National Institute of Dental Research to serve as the test pieces mould. Using the six test piece moulds, light cured acrylic resin test samples were fabricated. The test samples were trimmed and polished to meet the standardized measurements. A total of 240 test sample (6 samples for each patient) for 20 completely edentulous patients with maxillary tori and 20 completely edentulous patients without tori were made for the study. The test pieces were attached to dental floss to prevent any accidentally aspiration during the study.
Study: NCT00290550

Intervention type: DRUG
Group type: OTHER
Intervention: MK0457
Description: IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
Study: NCT02064296

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Needle acupuncture (Traditional Acupuncture)
Description: This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device (AS Super 4 digital needle stimulator).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture (Non-traditional Acupuncture)
Description: For non-traditional acupuncture, a laser acupuncture device (Vita Laser 650, Lhasa OMS) will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
Study: NCT00821600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone IR and LAI formulation
Description: 1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
Study: NCT01626690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bair-Paws Warming Device
Description: Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bair-Hugger Warming Device
Description: Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
Study: NCT04831814

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near Focus NBI
Description: Colonoscopy with near focus narrowing band imaging technology . Optical specifications include a 2 mm near field focal depth. Optical diagnosis of polyps were according to NICE and WASP, respectively.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Focus NBI
Description: Colonoscopy with narrow band imaging technology.Optical diagnosis of polyps were according to NICE and WASP, respectively.
Study: NCT03161379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study: NCT03151200

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer based binocular treatment
Description: Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
Study: NCT03161379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVAX Pancreas Vaccine
Description: Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
Study: NCT03161379

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation (SBRT)
Description: SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
Study: NCT04513301

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab (200 mg q3w ×2 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab (200 mg q3w ×2 cycle)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: RT 50-60Gy/25-30f
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
Study: NCT03864419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes
Study: NCT03864419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab and Hyaluronidase Human
Description: Given SC
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin
Description: Infusion over 60 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
Study: NCT03864419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caelyx
Description: Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
Study: NCT04603118

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Study: NCT03838081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger State Anxiety Inventory (STAI-S),
Description: STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
Study: NCT03838081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger State Anxiety Inventory (STAI-S),
Description: STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger State Anxiety Inventory (STAI-S),
Description: STAI is one of the most frequently used scales in anxiety research, although it is not a specific scale for dental anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental Fear Scale (DFS)
Description: DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental Fear Scale (DFS)
Description: DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental Fear Scale (DFS)
Description: DFS is a scale developed by Kleinknecht used to determine dental fear in different dimensions. This is a Likert-type scale with a score of 1-5. It has 20 items. It examines the level of fear in terms of dentist avoidance, somatic symptoms of fear, and fear of various applications in dentistry practice
Study: NCT01490047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human TNF-α
Description: Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
Study: NCT03838081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Dental Anxiety Scale (MDAS)
Description: MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Dental Anxiety Scale (MDAS)
Description: MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Dental Anxiety Scale (MDAS)
Description: MDAS was developed by Humphris et al. by adding a question related to injection. The scale consists of five-point Likert-type rating with five options. The scoring in this scale varies between 5 and 25

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable
Study: NCT02481934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NKAE cells infusion
Description: Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
Study: NCT03838081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Description: VAS is ideal for evaluating situations that cannot be measured using digital and oral information. In the present study, a scale comprising 100-mm closed-end line was used to measure the anxiety level. One end of the scale was labeled as no anxiety and the other end as maximum anxiety imaginable
Study: NCT02481934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
Study: NCT00646425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: 40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match basiliximab
Study: NCT01902329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMA
Description: azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD33A
Description: Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
Study: NCT02563236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parabolic flight
Study: NCT01389492

Intervention type: OTHER
Group type: OTHER
Intervention: frozen meat cutlets meal
Description: 250 g of meat cutlets

Intervention type: OTHER
Group type: OTHER
Intervention: frozen meat cutlets meal
Description: 250 g of meat cutlets

Intervention type: OTHER
Group type: OTHER
Intervention: frozen meat cutlets meal
Description: 250 g of meat cutlets

Intervention type: OTHER
Group type: OTHER
Intervention: frozen meat cutlets meal
Description: 250 g of meat cutlets

Intervention type: OTHER
Group type: OTHER
Intervention: meat meals
Description: 250 g of meat meal for 4 days
Study: NCT02995239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 formulation 2
Description: CJ-12420 formulation 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ-12420 formulation 1
Description: CJ-12420 formulation 1